- Home
- LYFT vs APGE Comparison
LYFT vs APGE Comparison
Compare LYFT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | 3913 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.7B |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LYFT | APGE |
|---|---|---|
| Price | $12.85 | $77.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 30 | 13 |
| Target Price | $20.14 | ★ $109.25 |
| AVG Volume (30 Days) | ★ 14.9M | 1.0M |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | N/A |
| EPS | ★ 6.81 | N/A |
| Revenue | ★ $6,316,261,000.00 | N/A |
| Revenue This Year | $17.73 | N/A |
| Revenue Next Year | $12.39 | N/A |
| P/E Ratio | $1.91 | ★ N/A |
| Revenue Growth | ★ 9.16 | N/A |
| 52 Week Low | $9.66 | $26.20 |
| 52 Week High | $25.54 | $85.04 |
Technical Indicators
Market Signals| Indicator | LYFT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 60.14 |
| Support Level | N/A | $73.06 |
| Resistance Level | $14.24 | $81.04 |
| Average True Range (ATR) | 0.45 | 4.62 |
| MACD | 0.08 | 0.96 |
| Stochastic Oscillator | 18.01 | 73.26 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.